UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 3, 2011

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At August 8, 2011, 7,802,126,616 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended

July 3, 2011

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended July 3, 2011 and July 4, 2010

Condensed Consolidated Balance Sheets as of July 3, 2011 and December 31, 2010

Condensed Consolidated Statements of Cash Flows for the six months ended July 3, 2011 and July 4, 2010

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

39

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

40

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

77

Item 4.

Controls and Procedures

77

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

77

Item 1A.

Risk Factors

78

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

78

Item 3.

Defaults Upon Senior Securities

78

Item 5.

Other Information

78

Item 6.

Exhibits

79

Signature

80

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

July 3,

2011

July 4,

2010

July 3,

2011

July 4,

2010

Revenues

16,984

17,132

33,486

33,708

Costs and expenses:

Cost of sales(a)

3,805

3,684

7,498

7,886

Selling, informational and administrative expenses(a)

4,973

4,774

9,476

9,177

Research and development expenses(a)

2,237

2,181

4,328

4,402

Amortization of intangible assets

1,395

1,407

2,771

2,816

Acquisition-related in-process research and development charges

74

Restructuring charges and certain acquisition-related costs

479

885

1,373

1,591

Other deductions net

413

275

1,240

687

Income from continuing operations before provision for taxes on income

3,682

3,926

6,800

7,075

Provision for taxes on income

1,094

1,472

1,988

2,607

Income from continuing operations

2,588

2,454

4,812

4,468

Discontinued operations:

Income from operations net of tax

30

31

40

50

Gain on sale of discontinued operations net of tax

Discontinued operations net of tax

30

31

40

52

Net income before allocation to noncontrolling interests

2,618

2,485

4,852

4,520

Less: Net income attributable to noncontrolling interests

10

20

19

Net income attributable to Pfizer Inc.

2,610

2,475

4,832

4,501

Earnings per share basic: (b)

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.33

0.30

0.60

0.55

Discontinued operations net of tax

0.01

0.01

Net income attributable to Pfizer Inc. common shareholders

0.33

0.31

0.61

0.56

Earnings per share diluted: (b)

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.33

0.30

0.60

0.55

Discontinued operations net of tax

0.01

0.01

Net income attributable to Pfizer Inc. common shareholders

0.33

0.31

0.61

0.56

Weighted-average shares used to calculate earnings per common share:

Basic

7,875

8,046

7,929

8,053

Diluted

7,935

8,072

7,980

8,085

Cash dividends paid per common share

0.20

0.18

0.40

0.36

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 11B. Goodwill and Other Intangible Assets: Other Intangible Assets.

(b)

EPS amounts may not add due to rounding.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(millions of dollars)

July 3,

2011

Dec. 31,

2010

(Unaudited)

Assets

Cash and cash equivalents

3,096

1,735

Short-term investments

22,388

26,277

Accounts receivable, less allowance for doubtful accounts

15,192

14,426

Short-term loans

462

467

Inventories

8,597

8,275

Taxes and other current assets

9,271

8,394

Assets of discontinued operations and other assets held for sale

1,478

1,439

Total current assets

60,484

61,013

Long-term investments and loans

10,207

9,747

Property, plant and equipment, less accumulated depreciation

18,281

18,645

Goodwill

45,107

43,928

Identifiable intangible assets, less accumulated amortization

57,059

57,555

Taxes and other noncurrent assets

4,761

4,126

Total assets

195,899

195,014

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

5,988

5,603

Accounts payable

3,698

3,994

Dividends payable

1,637

1,601

Income taxes payable

1,849

951

Accrued compensation and related items

1,815

2,080

Other current liabilities

15,303

14,256

Liabilities of discontinued operations

181

151

Total current liabilities

30,471

28,636

Long-term debt

35,723

38,410

Pension benefit obligations

5,852

6,194

Postretirement benefit obligations

3,057

3,035

Noncurrent deferred tax liabilities

20,072

18,628

Other taxes payable

6,829

6,245

Other noncurrent liabilities

4,932

5,601

Total liabilities

106,936

106,749

Preferred stock

47

52

Common stock

445

444

Additional paid-in capital

71,095

70,760

Employee benefit trusts

(3

(7

Treasury stock

(26,471

(22,712

Retained earnings

44,320

42,716

Accumulated other comprehensive loss

(952

(3,440

Total Pfizer Inc. shareholders equity

88,481

87,813

Equity attributable to noncontrolling interests

482

452

Total shareholders equity

88,963

88,265

Total liabilities and shareholders equity

195,899

195,014

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(millions of dollars)

July 3,

2011

July 4,

2010

Operating Activities:

Net income before allocation to noncontrolling interests

4,852

4,520

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by/(used in) operating activities:

Depreciation and amortization

4,409

4,264

Share-based compensation expense

244

243

Asset write-offs and impairment charges

573

833

Acquisition-related in-process research and development charges

74

Deferred taxes from continuing operations

505

1,610

Other non-cash adjustments

34

(92

Benefit plan contributions (in excess of)/less than expense

(264

234

Other changes in assets and liabilities, net of acquisitions and divestitures

187

(13,173

Net cash provided by/(used in) operating activities

10,540

(1,487

Investing Activities:

Purchases of property, plant and equipment

(608

(678

Purchases of short-term investments

(6,559

(3,531

Proceeds from redemptions and sales of short-term investments net

12,837

11,048

Purchases of long-term investments

(3,193

(1,481

Proceeds from redemptions and sales of long-term investments

1,572

3,156

Acquisitions, net of cash acquired

(3,169

Other investing activities

206

519

Net cash provided by investing activities

1,086

9,033

Financing Activities:

Increase in short-term borrowings

4,868

3,169

Principal payments on short-term borrowings net

(4,935

(7,321

Principal payments on long-term debt

(3,481

(2

Purchases of common stock

(3,679

(500

Cash dividends paid

(3,159

(2,995

Other financing activities

64

77

Net cash used in financing activities

(10,322

(7,572

Effect of exchange-rate changes on cash and cash equivalents

57

(75

Net increase/(decrease) in cash and cash equivalents

1,361

(101

Cash and cash equivalents at beginning of period

1,735

1,978

Cash and cash equivalents at end of period

3,096

1,877

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

737

11,311

Interest

1,337

1,342

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and six-month periods ended May 29, 2011, and May 30, 2010. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to discontinued operations (see Note 4. Discontinued Operations) and segment reporting (see Note 15. Segment, Product and Geographic Area Information).

On January 31, 2011, we completed the tender offer for all of the outstanding shares of common stock of King Pharmaceuticals, Inc. (King) and acquired approximately 92.5% of the outstanding shares for approximately $3.3 billion in cash. On February 28, 2011, we acquired the remaining outstanding shares of King for approximately $300 million in cash (for additional information, see Note 3. Acquisition of King Pharmaceuticals, Inc). Commencing from January 31, 2011, our financial statements include the assets, liabilities, operating results and cash flows of King. Therefore, in accordance with our domestic and international reporting periods, our condensed consolidated financial statements for the six months ended July 3, 2011 reflect approximately five months of King s U.S. operations and approximately four months of King s international operations.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2010.

Note 2. Adoption of New Accounting Policies

The provisions of the following new accounting standards were adopted as of January 1, 2011 and did not have a significant impact on our condensed consolidated financial statements:

New guidelines that address the recognition and presentation of the annual fee paid by pharmaceutical companies beginning on January 1, 2011 to the U.S. Treasury as a result of U.S. Healthcare Legislation. As a result of adopting this new standard, we are recording the annual fee ratably throughout the year in the Selling, informational and administrative expenses line item in our condensed consolidated statement of income.

An amendment to the guidelines that address the accounting for multiple-deliverable arrangements to enable companies to account for certain products or services separately rather than as a combined unit.

Note 3. Acquisition of King Pharmaceuticals, Inc.

On January 31, 2011 (the acquisition date), we completed our tender offer for all of the outstanding shares of common stock of King at a purchase price of $14.25 per share in cash and acquired approximately 92.5% of the outstanding shares. On February 28, 2011, we acquired all of the remaining shares of King for $14.25 per share in cash. As a result, the total fair value of consideration transferred for King was approximately $3.6 billion in cash ($3.2 billion, net of cash acquired).

King s principal businesses consist of a prescription pharmaceutical business focused on delivering new formulations of pain treatments designed to discourage common methods of misuse and abuse; the Meridian auto-injector business for emergency drug delivery, which develops and manufactures the EpiPen; an established products portfolio; and an animal health business that offers a variety of feed-additive products for a wide range of species.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(millions of dollars)

Amounts

Recognized as of

Acquisition Date

(Provisional)

Working capital, excluding inventories

190

Inventories

338

Property, plant and equipment

413

Identifiable intangible assets, excluding in-process research and development

1,781

In-process research and development

301

Net tax accounts

(373

All other long-term assets and liabilities, net

114

Total identifiable net assets

2,764

Goodwill

791

Net assets acquired/total consideration transferred

3,555

As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $200 million, virtually all of which is expected to be collected.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recorded as part of the acquisition of King includes the following:

the expected synergies and other benefits that we believe will result from combining the operations of King with the operations of Pfizer;

any intangible assets that do not qualify for separate recognition, as well as future, yet unidentified projects and products; and

the value of the going-concern element of King s existing businesses (the higher rate of return on the assembled collection of net assets versus if Pfizer had acquired all of the net assets separately).

Goodwill is not amortized and is not deductible for tax purposes. While the allocation of goodwill among reporting units is not complete, we expect that substantially all of the goodwill will be related to our biopharmaceutical reporting units (see Note 11. Goodwill and Other Intangible Assets for additional information).

The assets and liabilities arising from contingencies recognized at acquisition date, which are subject to change, are not significant to Pfizer s financial statements.

The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

Amounts for intangibles, inventory and property, plant and equipment (PP&E), pending finalization of valuation efforts for acquired intangible assets and inventory and the confirmation of the physical existence and condition of certain inventory and PP&E assets.

Amounts for environmental contingencies, pending the finalization of our assessment and valuation of environmental matters.

Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.

Amounts for income tax assets, receivables and liabilities pending the filing of King s pre-acquisition tax returns and the receipt of information from taxing authorities, which may change certain estimates and assumptions used.

The allocation of goodwill among reporting units.

The following table presents information for King that is included in Pfizer s condensed consolidated statement of income from the acquisition date, January 31, 2011, through Pfizer s second-quarter 2011 domestic and international quarter-ends:

(millions of dollars)

King s Operations

Included in Pfizer s

Second-Quarter

2011 Results

King s Operations

Included in Pfizer s

Six-Month

2011 Results

Revenues

357

581

Loss from continuing operations attributable to Pfizer Inc. common shareholders(a)

(5

(74

(a)

Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($61 million pre-tax in the second quarter of 2011 and $119 million pre-tax in the first six months of 2011), amortization of identifiable intangible assets acquired from King ($43 million pre-tax in the second quarter of 2011 and $71 million pre-tax in the first six months of 2011) and restructuring and integration costs ($63 million pre-tax in the second quarter of 2011 and $159 million pre-tax in the first six months of 2011).

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:

Pro Forma Consolidated Results

Three Months

Ended

Six Months Ended

(millions of dollars, except per share data)

July 4,

2010

July 3,

2011

July 4,

2010

Revenues

17,465

33,595

34,414

Income from continuing operations attributable to Pfizer Inc. common shareholders

2,408

5,008

4,314

Diluted earnings per share attributable to Pfizer Inc. common shareholders

0.30

0.63

0.53

The unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition. The unaudited pro forma consolidated results reflect the historical financial information of Pfizer and King, adjusted for the following pre-tax amounts:

Elimination of King s historical intangible asset amortization expense (approximately $38 million in the second quarter of 2010, $6 million in the first six months of 2011 and $79 million in the first six months of 2010).

Additional amortization expense (approximately $43 million in the second quarter of 2010 and $86 million in the first six months of 2010) related to the fair value of identifiable intangible assets acquired.

Additional depreciation expense (approximately $9 million in the second quarter of 2010, $3 million in the first six months of 2011 and $17 million in the first six months of 2010) related to the fair value adjustment to property, plant and equipment acquired.

Adjustment related to the fair value adjustments to acquisition-date inventory estimated to have been sold (addition of $61 million charge in the second quarter of 2010, elimination of $119 million charge in the first six months of 2011 and addition of $119 million charge in the first six months of 2010).

Adjustment for acquisition-related costs directly attributable to the acquisition (addition of $63 million of charges in the second quarter of 2010, elimination of $181 million of charges in the first six months of 2011 and addition of $181 million of charges in the first six months of 2010, reflecting charges incurred by both King and Pfizer).

Note 4. Discontinued Operations

We evaluate our businesses and product lines periodically for their strategic fit within our operations. In 2011, we decided to sell our Capsugel business. In connection with the decision to sell this business, for all periods presented, the operating results associated with this business have been reclassified into Discontinued operations net of tax in the Condensed Consolidated Statements of Income, and the assets and liabilities associated with this business have been reclassified into Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in the Condensed Consolidated Balance Sheets.

On April 4, 2011, we announced that we had entered into an agreement to sell Capsugel to an affiliate of Kohlberg Kravis Roberts & Co. L.P. for $2.375 billion in cash. The transaction closed on August 1, 2011.

The following amounts, substantially all of which relate to our Capsugel business, have been segregated from continuing operations and included in Discontinued operations net of tax in our Condensed Consolidated Statements of Income:

Three Months Ended

Six Months Ended

(millions of dollars)

July 3,

2011

July 4,

2010

July 3,

2011

July 4,

2010

Revenues

214

195

391

369

Pre-tax income from discontinued operations

44

47

72

77

Provision for taxes

(14

(16

(32

(27

Income from discontinued operations net of tax

30

31

40

50

Pre-tax gain on sale of discontinued operations

Provision for income taxes

(1

Discontinued operations net of tax

30

31

40

52

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following assets and liabilities, which include assets and liabilities held for sale related to our Capsugel business, and other assets held for sale, have been segregated and included in Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate, in our Condensed Consolidated Balance Sheets:

(millions of dollars)

July 3,

2011

Dec. 31,

2010

Accounts receivable

193

186

Inventories

149

130

Taxes and other current assets

25

47

Property, plant and equipment

1,041

1,009

Goodwill

20

19

Identifiable intangible assets

Taxes and other noncurrent assets

44

45

Assets of discontinued operations and other assets held for sale

1,478

1,439

Current liabilities

154

124

Other liabilities

27

27

Liabilities of discontinued operations

181

151

Net cash flows of our discontinued operations from each of the categories of operating, investing and financing activities were not significant.

Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity

We incur significant costs in connection with acquiring businesses and restructuring and integrating acquired businesses and in connection with our global cost-reduction and productivity initiatives. For example:

for our cost-reduction and productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and

for our acquisition activity, we typically incur costs that can include transaction costs, integration costs (such as expenditures for consulting and systems integration) and restructuring charges, related to employees, assets and activities that will not continue in the combined company.

On February 1, 2011, we announced a new research and productivity initiative to accelerate our strategies to improve innovation and overall productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We incurred the following costs in connection with our cost-reduction and productivity initiatives and acquisition activity, such as King (acquired in 2011) and Wyeth (acquired in 2009):

Three Months Ended

Six Months Ended

(millions of dollars)

July 3,

2011

July 4,

2010

July 3,

2011

July 4,

2010

Transaction costs(a)

13

23

13

Integration costs(b)

201

211

380

419

Restructuring charges(c):

Employee termination costs

189

118

856

576

Asset impairments

33

497

58

503

Other

43

55

56

80

Restructuring charges and certain acquisition-related costs

479

885

1,373

1,591

Additional depreciation asset restructuring (d)

Cost of sales

171

113

343

126

Selling, informational and administrative expenses

23

103

30

163

Research and development expenses

168

232

20

Total additional depreciation asset restructuring

362

216

605

309

Implementation costs(e)

Research and development expenses

10

20

Total implementation costs

10

20

Total costs associated with cost-reduction initiatives and

acquisition activity

851

1,101

1,998

1,900

(a)

Transaction costs represent external costs directly related to business combinations and primarily include expenditures for banking, legal, accounting and other similar services.

(b)

Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and systems integration.

(c)

From the beginning of our cost-reduction and transformation initiatives in 2005 through July 3, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 55,400 employees, mainly in manufacturing and sales and research, of which approximately 39,100 employees have been terminated as of July 3, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

These restructuring charges in 2011 are associated with the following:

For the three months ended July 3, 2011, Primary Care operating segment ($87 million), Specialty Care and Oncology operating segment ($7 million), Established Products and Emerging Markets operating segment ($12 million), Animal Health and Consumer Healthcare operating segment ($4 million), research and development operations ($51 million), manufacturing operations ($81 million) and Corporate ($23 million).

For the six months ended July 3, 2011, Primary Care operating segment ($133 million), Specialty Care and Oncology operating segment ($42 million), Established Products and Emerging Markets operating segment ($15 million), Animal Health and Consumer Healthcare operating segment ($14 million), Nutrition operating segment ($2 million), research and development operations ($473 million), manufacturing operations ($156 million) and Corporate ($135 million).

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)

Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction and productivity initiatives.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The components of restructuring charges associated with all of our cost-reduction and productivity initiatives and acquisition activity follow:

Costs Incurred

Activity

Accrual

(millions of dollars)

2005-2011

Through

July 3,

2011(a)

As of

July 3,

2011(b)

Employee termination costs

9,667

7,395

2,272

Asset impairments

2,366

2,366

Other

958

875

83

Total restructuring charges

12,991

10,636

2,355

(a)

Includes adjustments for foreign currency translation.

(b)

Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($657 million).

Note 6. Other (Income)/Deductions Net

The following table sets forth details related to amounts recorded in Other deductions net:

Three Months Ended

Six Months Ended

(millions of dollars)

July 3,

2011

July 4,

2010

July 3,

2011

July 4,